Immunotech Therapeutics Named to 2024 China Hidden Unicorn Top 500 List Amid IPO Filing
Imunopharm
Developer of Gene and Cell Therapy Technologies
On November 5, 2024, the 2024 China's Top 500 Hidden Unicorn Enterprises Conference was held in Qingdao High-tech Zone, Shandong. The conference, jointly organized by the Qingdao Municipal People's Government and the Research Center for Chinese Private Enterprises at Renmin University of China, took "Winning with Unicorns, Creating a New Future" as its theme. It brought together more than 200 enterprise representatives, venture capital experts, and scholars from across China to discuss development opportunities and challenges in emerging industries.
Beijing Yimiaoshenzhou Medical Techology Co., Ltd. award position is right 3.
The conference released the "2024 China Hidden Unicorn Enterprise 500 Strong Development Report" and the "2024 China Hidden Unicorn Enterprise 500 Strong Ranking".Beijing Yimiao Shenzhou Medical Technology Co., Ltd. ("Yimiao Shenzhou") successfully ranked on the "2024 China's 500 Strong Hidden Unicorns List" with its independent innovation strength and industry development potential in China's gene and cell drug field.
Beijing Yimiaoshenzhou Medical Techology Co., Ltd. 2024 China Hidden Unicorn Enterprise 500 Strong Medal
The inclusion in the 2024 China Hidden Unicorn 500 Strong list is an affirmation of Beijing Yimiaoshenzhou Medical Techology Co., Ltd.'s innovative development achievements and technological advantages in the field of proprietary gene and cell therapy drugs. It also represents high recognition of the company’s continuous innovation, outstanding industry influence, and future growth potential. Since the beginning of this year, Yimiao神州 has achieved several milestone breakthroughs in CAR-T drug research and development, cumulatively obtaining seven clinical trial approvals for Class I new drugs. Its product pipeline covers hematological tumors, solid tumors, and autoimmune diseases. Among them, the company's first CAR-T product, IM19, has completed clinical trials and reached a commercialization partnership with Huadong Medicine. Additionally, IM96, for the treatment of metastatic colorectal cancer, and ZM001, for systemic lupus erythematosus, have successively received clinical trial approvals from the National Medical Products Administration.
Technological innovation is a key driving force for industrial upgrading and socio-economic development. As a hidden unicorn enterprise, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. will continue to adhere to independent innovation, focus on patients, and prioritize clinical value. The company will increase R&D efforts, accelerate the R&D process, and continuously promote product and technology upgrades to bring safer, more effective, and lower-cost CAR-T products to more patients with serious diseases such as malignant tumors and autoimmune disorders. It aims to contribute to the high-quality development of China's health care industry.
// About Yimiao Shenzhou //
Yimiao Shenzhou, established in 2015 with its headquarters in Beijing, is a leading clinical-stage biopharmaceutical company driven by the mission of "making cancer no longer an incurable disease." The company focuses on applying innovative gene and cell therapy technologies to treat major diseases such as cancer and autoimmune disorders. To date, Yimiao Shenzhou has completed nine rounds of strategic financing and owns a one-stop, self-developed gene and cell therapy R&D and industrialization platform. It possesses several core technologies, was awarded the top prize in the National Disruptive Technology Innovation Competition, and obtained seven clinical trial approvals for Class 1 new drugs as well as Beijing’s first-ever Drug Manufacturing License for gene and cell therapies. Its R&D pipeline covers hematological malignancies like lymphoma, leukemia, and myeloma, as well as solid tumors such as liver cancer, colorectal cancer, and melanoma, making it a leader in the field of gene and cell therapy.
The company has undertaken more than 10 national and provincial scientific research projects, including the Special Project of the National Key Research and Development Program by the Ministry of Science and Technology, the Major Innovation Project for Science and Technology under the "2030 Health China" initiative led by the National Health Commission, the "Challenge Leader" technical project on cell therapy from the National Innovation Center, and the Beijing Municipal Major Science and Technology Special Project. It has obtained significant qualifications such as a National High-tech Enterprise, a Beijing-based specialized, refined, distinctive, and innovative enterprise, a Frontier Technology Enterprise in Zhongguancun, a Zhongguancun High-tech Enterprise, and a Postdoctoral Research Workstation. The team has been honored with awards such as the Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, Beijing Outstanding Engineer, Haiying Talent of Haidian District in Beijing, Xinguomen Leading Talent of Daxing District in Beijing, the Gold Award (First Place) at Tsinghua University’s President's Cup Innovation Challenge, MIT's "35 Innovators Under 35," and Fortune Magazine’s "40 Under 40" Business Elite.
